Lundbeck Q3 2019 Financial Results

Total molecule sales (gross) - USDM 52 NEW 1.250 Abilify Maintena 1.000 1.200 Trintellix 5mg-10mg-20mg tablets vortioxetine Brintellix vortioxetine 1.000 +58% 800 750 +80% 600 500 400 250 200 0 0 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 1.000 REXULTI 800 600 400 200 +161% 0 2015 2016 2017 2018 Source: IMS * * * Abilify Maintena: US approval (Feb. 2013); EU approval (Nov. 2013) Brintellix/Trintellix: US approval (Oct. 2013); EU approval (Dec. 2013); Japan approval (Sep. 2019) Rexulti: US approval (Jul. 2015); EU approval (Jul. 2018); Japan approval (Jan. 2018 - NOT Lundbeck territory) Lundbeck

View entire presentation